Cyclopropylmethanamines for Selective 5-HT2C Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current 5-HT(2C) receptor agonists face challenges in achieving selective activation with minimal effect on 5-HT(2A) and 5-HT(2B) receptors, leading to side effects such as cardiac valvulopathy and hallucinations, and there is a need for compounds that effectively treat psychiatric disorders and obesity with improved selectivity.
Innovation Solution
Development of novel 5-HT(2C) receptor agonists with specific structural modifications, such as the (+) enantiomer of compounds with a 2-phenylcyclopropylmethylamine scaffold, which exhibit high selectivity over 5-HT(2A) and 5-HT(2B) receptors, enhancing therapeutic efficacy while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current 5-HT(2C) receptor agonists are used to achieve therapeutic effects, then treatment efficacy for psychiatric disorders and obesity is improved, but selectivity against 5-HT(2A) and 5-HT(2B) receptors deteriorates leading to side effects
Solution Approach 1:
The patent applies local quality by introducing specific substitutions at defined positions on the phenylcyclopropylmethylamine scaffold. For example, placing electron-withdrawing groups at the 2-position and electron-donating groups at the 5-position of the phenyl ring creates localized electronic differences that enhance 5-HT(2C) selectivity while maintaining agonist activity, thereby reducing off-target effects on 5-HT(2A) and 5-HT(2B) receptors
Solution Approach 2:
The patent systematically varies molecular parameters including substituent types (halogens, alkyl groups, alkoxy groups), their positions, and stereochemistry (R/S configurations) to optimize the balance between therapeutic efficacy and receptor selectivity. These parameter changes allow fine-tuning of the compound's interaction with different 5-HT2 receptor subtypes
2Object-affected harmful factors
If high selectivity for 5-HT(2C) receptor is achieved through structural modifications, then side effects are reduced, but compound complexity increases
Solution Approach 1:
The patent segments the molecular structure into distinct functional regions: the phenylcyclopropylmethylamine core scaffold provides the basic 5-HT2C agonist activity, while specific substituents at defined positions (2-position electron-withdrawing groups, 5-position electron-donating groups) act as selectivity-determining elements. This segmentation allows independent optimization of activity and selectivity
Solution Approach 2:
The patent employs asymmetry through chiral centers at the cyclopropyl ring and asymmetric substitution patterns on the phenyl ring. The (R)- and (S)-enantiomers exhibit different selectivity profiles, and the use of asymmetric substitution (different groups at different positions) creates molecular chirality that enhances selectivity for 5-HT(2C) over other 5-HT2 subtypes
3Object-affected harmful factors
If selective 5-HT(2C) agonists are developed to avoid cardiac valvulopathy and hallucinations, then patient safety is improved, but drug development challenges increase due to high conservation of molecular determinants
Solution Approach 1:
The patent systematically explores changes in molecular parameters including substituent identity (F, Cl, Br, CF3, OCH3, etc.), substituent positions (2-, 3-, 4-, 5-positions), and stereochemical configuration to identify combinations that maximize 5-HT(2C) selectivity. This systematic parameter variation allows navigation through the complex chemical space to find compounds with desired selectivity profiles
Solution Approach 2:
The patent replaces the trial-and-error approach to drug discovery with a rational design strategy based on structure-activity relationship (SAR) analysis. By establishing structure-selectivity relationships through systematic modification of the phenylcyclopropylmethylamine scaffold, the patent substitutes empirical screening with mechanism-guided optimization
Data Source
Figure 1
AI summary
Disclosed are 2-phenyl-cyclopropylmethanamines which are selective 5-HT(2C) receptor agonists and are used in the treatments of diseases and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.